Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01834729 · ClinicalTrials.gov registry record · Phase 2
Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT01834729: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT01834729 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 74 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01834729, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
This study is designed to better understand the effects of effects of stress, relaxation, and a medication alfuzosin on bowel control and emptying in healthy people and patients with bowel problems.
Interventions
- OTHER Placebo
- DRUG Alfuzosin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2013-03 |
| Est. Completion | 2017-09-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01834729
The ClinicalTrials.gov registry entry for NCT01834729 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01834729 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01834729 about?
NCT01834729 is a clinical study titled "Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions". This study is designed to better understand the effects of effects of stress, relaxation, and a medication alfuzosin on bowel control and emptying in healthy people and patients with bowel problems.
What is the current status of trial NCT01834729?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2013-03. Estimated completion is 2017-09-06.
What interventions are being tested in trial NCT01834729?
The interventions under investigation include: Placebo (OTHER), Alfuzosin (DRUG).
Who is sponsoring clinical trial NCT01834729?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.